Mahmood Ladha
President chez DOVA PHARMACEUTICALS, INC.
Postes actifs de Mahmood Ladha
Sociétés | Poste | Début | Fin |
---|---|---|---|
SWEDISH ORPHAN BIOVITRUM AB | Corporate Officer/Principal | 01/01/2019 | - |
DOVA PHARMACEUTICALS, INC. | President | 12/11/2019 | - |
Historique de carrière de Mahmood Ladha
Anciens postes connus de Mahmood Ladha
Sociétés | Poste | Début | Fin |
---|---|---|---|
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Directeur/Membre du Conseil | - | - |
Corporate Officer/Principal | - | - |
Formation de Mahmood Ladha
University of South Carolina | Masters Business Admin |
Statistiques
Internationale
Suède | 3 |
Etats-Unis | 3 |
Opérationnelle
Corporate Officer/Principal | 2 |
Masters Business Admin | 1 |
Undergraduate Degree | 1 |
Sectorielle
Health Technology | 3 |
Consumer Services | 2 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
Entreprise privées | 2 |
---|---|
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Commercial Services |
Dova Pharmaceuticals, Inc.
Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dova Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the acquisition, development and commercialization of drug candidates for rare diseases. It focuses on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist. The company was founded on March 24, 2016 and is headquartered in Durham, NC. | Health Technology |
- Bourse
- Insiders
- Mahmood Ladha
- Expérience